Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$21K-9.655,387 shs2,425 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.24
-46.7%		$28.13
$0.20
▼
$28,125.00
$10K1.59543,448 shs22.14 million shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Trevena, Inc. stock logo
TRVN
Trevena
$0.07
$0.01
$0.00
▼
$1.50
$63K-1.99727 shs23 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-37.50%-91.23%-98.53%
CDT Equity Inc. stock logo
CDT
CDT Equity
-46.67%-71.29%-95.62%-99.73%-100.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+450.00%+16,400.00%+494.59%+450.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$21K-9.655,387 shs2,425 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.24
-46.7%		$28.13
$0.20
▼
$28,125.00
$10K1.59543,448 shs22.14 million shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Trevena, Inc. stock logo
TRVN
Trevena
$0.07
$0.01
$0.00
▼
$1.50
$63K-1.99727 shs23 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-37.50%-91.23%-98.53%
CDT Equity Inc. stock logo
CDT
CDT Equity
-46.67%-71.29%-95.62%-99.73%-100.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+450.00%+16,400.00%+494.59%+450.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00
N/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
1.00
SellN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NAVB, CDT, CARM, and TRVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
CDT Equity Inc. stock logo
CDT
CDT Equity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.14N/AN/A($11.07) per share-0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
CDT Equity Inc. stock logo
CDT
CDT Equity
-$39.22M-$83,857.75N/AN/AN/AN/A-72.25%-55.44%N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2026 (Estimated)

Latest NAVB, CDT, CARM, and TRVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026N/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$0.1237N/AN/AN/A$4.66 millionN/A
11/5/2026N/A
Trevena, Inc. stock logo
TRVN
Trevena
-$50.00N/AN/AN/A$0.78 millionN/A
8/12/2026Q2 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$217.75N/A-$8.71N/AN/A
7/15/2026Q1 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$1,390.00N/A-$55.60N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A
0.13
0.13
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
CDT Equity Inc. stock logo
CDT
CDT Equity
3.29%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
CDT Equity Inc. stock logo
CDT
CDT Equity
7.34%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
4641.85 million38.91 millionNo Data
CDT Equity Inc. stock logo
CDT
CDT Equity
430,00029,000Not Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
23959,000841,000No Data

Recent News About These Companies

Trevena stock held at USD 0.01 as volume reached 257 shares
October 6, 2026  |  ad-hoc-news.deA
Trevena (NASDAQ:TRVN) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090708
Trevena stock holds near its yearly range as trading data reset
September 22, 2026  |  ad-hoc-news.deA
Trevena Inc.
May 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/TRVN/financials
Trevena Restructures China Royalty Rights to Exit Debt
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-restructures-china-royalty-rights-to-exit-debt?utm_source=marketbeat.com&utm_medium=referral
Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored
July 8, 2025  |  msn.comhttps://www.msn.com/en-us/sports/mlb/softball-conrad-weiser-s-alex-trevena-earns-statewide-player-of-the-year-award-5-other-berks-players-honored/ar-AA1IcIZz
Trevena, Inc. (TRVN) - Yahoo Finance
June 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TRVN/press-releases/
Trevena Enters Securities Exchange Agreement with Investor
May 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-enters-securities-exchange-agreement-with-investor?utm_source=marketbeat.com&utm_medium=referral
Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win
April 11, 2025  |  readingeagle.comR
Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater
March 9, 2025  |  msn.comhttps://www.msn.com/en-us/music/news/vanessa-hudgens-and-oliver-trevena-appear-at-expo-west-for-caliwater/ar-AA1Axb5h
JMP Securities downgrades Trevena (TRVN) to a Hold
December 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jmp-securities-downgrades-trevena-trvn-to-a-hold-1034177267
‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment
December 16, 2024  |  yahoo.comhttps://www.yahoo.com/entertainment/plane-actor-oliver-trevena-signs-153000870.html
Lyme Regis town councillor John Trevena stand down
December 11, 2024  |  bridportnews.co.ukB
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
December 10, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2381592/trevena-trvn-could-find-a-support-soon-here-s-why-you-should-buy-the-stock-now?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2381592
Trevena appoints new financial chief
November 29, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/trevena-appoints-new-financial-chief-93CH-3745129
Trevena Appoints Katrine Sutton as New CFO
November 27, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-appoints-katrine-sutton-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
HC Wainwright & Co. Downgrades Trevena (TRVN)
November 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-trevena-trvn/ar-AA1u9FYi
Trevena, Inc. Navigates Financial Challenges and Strategic Changes
November 9, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/trevena-inc-navigates-financial-challenges-and-strategic-changes/ar-AA1tMJqv
Chester County biopharm firm's latest layoffs impact its C-suite
November 7, 2024  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2024/11/07/trevena-chesterbrook-layoffs-c-suite-pain-medicine.html
Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review
November 7, 2024  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Rows of used vehicles parked in a lot outside a CarMax dealership building with its logo displayed.
CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
By Thomas Hughes | September 29, 2026
A candlestick stock price chart overlaid on a blurred urban skyline at dusk.
MarketBeat Week in Review – 09/28 - 10/02
By MarketBeat Staff | October 3, 2026
Split image showing a Carnival cruise ship at sea alongside a CarMax dealership lot with used cars displayed.
Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
By Jessica Mitacek | October 3, 2026
Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0005 0.00 (0.00%)
As of 10/14/2026 03:17 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

CDT Equity stock logo

CDT Equity NASDAQ:CDT

$0.24 -0.21 (-46.67%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$0.25 +0.01 (+3.33%)
As of 10/14/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.07 0.00 (0.00%)
As of 10/13/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas